Reza Mehrazin, MD
@MehrazinMD
Followers
3K
Following
4K
Media
209
Statuses
1K
Professor of Urology, Fellowship Director, Urologic Oncology @MountSinaiNYC |Views Mine| RT/Fav’s≠E.
Manhattan, New York.
Joined September 2012
Honored to receive the SUO ‘Paper of the Year.’ I am sincerely grateful to my mentors at Mount Sinai for their constant guidance, high standards, and generosity with their time,this recognition reflects their mentorship as much as the science. #SUO2025
Congratulations to our star ⭐️ fellow @ahmederaky for receiving the prestigious @SUO_YUO "Paper of the Year" award at the #SUO2025 ! We are proud of this outstanding achievement. @MountsinaiUro 🏆@DrJohnSfakianos @AshTewariMD
7
5
34
Congratulations to our star ⭐️ fellow @ahmederaky for receiving the prestigious @SUO_YUO "Paper of the Year" award at the #SUO2025 ! We are proud of this outstanding achievement. @MountsinaiUro 🏆@DrJohnSfakianos @AshTewariMD
2
3
46
> 80% systemic treatment free survival with Primary #RPLND in select patients with stage II seminoma @siadaneshmand #SIU2025Edinburgh
1
2
28
CILR26 - The Surgical Experience 📍 Rome, June 3-4-5 🌍 A unique opportunity to learn from the world's leading urologists. You simply can't miss it! @aleantonellibs1 @NYCRoboticTeam @RaviBarodUrol @RicBertolo @SimoneCrivella2 @MehrazinMD @minerviniandre @mdstifelman @AshTewariMD
0
8
28
Tonight we had the honor of celebrating @dytcmd ‘s endowment! It was surreal to be back at this great institution after a decade and hang out with old friends @UROncDoc ! Thanks @uretericbud for organizing the events. @benristau @UroCorrea @FCUroOnc
5
8
55
Loved my visit. @nycrobotics @MehrazinMD @NYCRoboticTeam @nwaingankar et al, thanks for the superb hospitality! What an awesome team with a couple of proud @FCUroOnc grads amongst them!
Great to have @uretericbud in #NYC at @MountsinaiUro as Visiting Professor. Even Better to get some time to catch up and have him spend time with the fellows! @LauraZuluagaJim @cristobalroman
@AshTewariMD
2
5
60
All star ⭐️ panel on #robotic #cystectomy #WCET25 @SocietySURS @Endo_Society @mdstifelman @MehrazinMD Monish Aron @BogdanaSchmidt @Dr_Jen_Linehan @RoboticsUrology
1
4
26
🚨 New in J Urol: Our team @MountsinaiUro evaluated [18F]-DCFPyL PSMA PET/CT for nodal staging in intermediate-risk #ProstateCancer. Could this imaging tool spare men unnecessary pelvic lymph node dissection (PLND)? 🧵👇 🔗
auajournals.org
Purpose:Pelvic lymph node dissection (PLND) remains standard for nodal staging in prostate cancer (PCa), yet its benefit in intermediate-risk PCa is controversial. Traditional imaging and nomograms...
1
1
8
A great collaborative effort on the molecular & therapeutic landscape of non–clear cell renal carcinoma (nccRCC) — from MET-driven pRCC to SMARCB1-deficient RMC. @MountsinaiUro
We just published a review article in Nature Reviews Urology @NatRevUrol Congratulations team: Prerna Nepali, @ahmederaky ,Kennedy, @MehrazinMD @NYCRoboticTeam and Natasha Kyprianou https://t.co/VM2mUpMCuZ
3
0
15
Can photos 🖼️ truly convey the depth of two incredible and transformative years of SUO fellowship training? @SUO_YUO I was extraordinarily fortunate to train under these giants @MehrazinMD, @DrJohnSfakianos , Dr. Peter Wiklund @AshTewariMD of urologic oncology at
We had the honor of graduating our first SUO fellow @ReubenBenDavid1 and on the same day we welcomed our 4th successful match Francis Simard. It has been a true pleasure to be involved in their training! @AshTewariMD @DrJohnSfakianos @SUO_YUO @MountsinaiUro
9
3
55
We had the honor of graduating our first SUO fellow @ReubenBenDavid1 and on the same day we welcomed our 4th successful match Francis Simard. It has been a true pleasure to be involved in their training! @AshTewariMD @DrJohnSfakianos @SUO_YUO @MountsinaiUro
5
3
46
Thank you @CILR2025 for showing this case! The data for robotic RPLND continues to mature … current literature has shown that it is a great option for select patients with retroperitoneal tumors!
Great robotic RPLND in 9cm mass by @NYCRoboticTeam @MehrazinMD showing excellent bowel management. And discussion w/ @JamesPorterMD clipping lymphatics especially left proximal & avoiding vascular injury @CILR2025 #CILR25
1
3
17
Preoperative ctDNA was detectable in 61% of patients with localized RCC…after surgery, 83.3% cleared ctDNA. Detectable minimal residual disease ctDNA had poor survival outcomes compared to undetectable MRD ctDNA
#AUA25 was a great opportunity to present our findings @MehrazinMD on the utility of ctDNA in RCC, both in predicting disease recurrence and when comparing its diagnostic performance to conventional imaging studies. Thank you @GUOncologyNow for highlighting these findings!
0
2
26
A wonderful meeting of minds to discuss early returns of sexual function following NS RP and hydro dissection and also SP Kidney and RPLND@nyc robotics @EUplatinum @NYCRoboticTeam @MehrazinMD @DrJohnSfakianos P Wiklund.
0
1
23
@NYCRoboticTeam @RoboticsUrology @alexmottrie @lee_c_zhao @MehrazinMD @UroRazzleDazzle @RamPathakMD Proud to be part of this international group who are all so focused on training time next generation on SP.
0
7
22
Great debate at robotics theater on extended LND for bladder after SWOG S1101. Have to admit still doing this for some patients. #AUA2025
@MehrazinMD @mdstifelman @JanetKukreja @pcvblack @Agarwal_CaB @saumyg @RyanNelson762 @nnavai
0
1
12
Great for preventing prolapse! @Agarwal_CaB Awesome technique thanks for sharing . #AUA2025
@MehrazinMD @mdstifelman @JanetKukreja @pcvblack @saumyg @RyanNelson762 @nnavai
2
2
25
Looking forward to running this session at the #AUA25 discussing techniques in Robotic Cystectomy with intracorporeal diversions with esteemed colleagues: @pcvblack @Agarwal_CaB @JanetKukreja @nnavai
This year SURS with @Endo_Society and @IntuitiveSurg producing the AUA Robotic Theatre program. 4 sessions lead by @md_eun @Dr_Jen_Linehan @DrewWagnermd @MehrazinMD. Rising stars, practical video review, dynamic panel to lean from. Check out last year’s promotional video with
1
3
24
Our results showing comparable outcomes between AT and CNAAT, raise the question of whether adding NT provides any further survival benefit when combined with modern adjuvant regimens.
New from the ROBUUST 2.0 Collaborative: In high-risk UTUC, combined neoadjuvant + adjuvant therapy showed no significant oncologic benefit over adjuvant therapy alone. Multicenter, propensity-matched analysis across 17 centers. Read: https://t.co/D2FPNjSgMz
@MehrazinMD @ricautor
0
1
6
These are rare tumors, yet, still captivate our minds! The 10% rule is far away from the truth! Just published in @UrologicClinics: Current management strategies for pheochromocytoma and paraganglioma! With excellent intra-op images ⏩ https://t.co/SlvWt3AdAY
@nwaingankar
0
2
11